Metallothionein 2A (MT2A) is the most expressed metallothionein (MT) isoform in prostate cells.
A number of studies have demonstrated altered MT2A expression in various human tumors, including prostate cancer. We conducted an association study to examine whether MT2A gene polymorphisms are associated with a risk of prostate cancer. Genotyping was conducted using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Three single nucleotide polymorphisms (SNPs), rs28366003, rs1610216, and rs10636, were genotyped in 358 prostate cancer cases and 406 population controls. One SNP in MT2A (rs28366003) showed a positive association with prostate cancer. Compared to homozygous common allele carriers, heterozygosity for the G variant (odds ratio (OR)=2.30, 95% confidence interval (CI): 1.50-3.47, P-trend < 0.0001; the OR assuming a dominant model 2.43 (95% CI: 1.62-3.61, Pdominant=0.001) after adjustment for age) had a significantly increased risk of prostate cancer in a Polish population. Our data suggest that the rs28366003 SNP in MT2A is associated with the risk of prostate cancer in a Polish population.
Written by:
Forma E, Krzeslak A, Wilkosz J, Jozwiak P, Szymczyk A, Rozanski W, Brys M. Are you the author?
Department of Cytobiochemistry, University of Łódź, Łódź, Poland.
Reference: Cancer Genet. 2012 Sep;205(9):432-5.
doi: 10.1016/j.cancergen.2012.05.005
PubMed Abstract
PMID: 22824183
UroToday.com Investigative Urology Section
